Veeva Systems, which provides cloud-based healthcare software, inked a deal with the biopharma UCB aimed at improving the patient experience in digital clinical trials.
Under the agreement, UCB will use Veeva’s ePRO and eConsent products to study participants and use the data collected to develop the strategic direction of such trials based on what is learned, the company said in a May 23 press release.
Financial terms of the agreement weren’t disclosed.
“The partnership between UCB and Veeva presents a significant opportunity to drive progress in clinical study execution," Iris Loew-Friedrich, M.D., Ph.D., executive vice president and UCB’s chief medical officer, said in the release. “By delivering digital clinical trials, we reduce the burden on participants and sites, improve trial accessibility, and ensure patients are at the heart of everything we do.”
In April, Veeva released the results of a study it conducted that found on-time data entry and data quality were the top challenges for medtech companies working with clinical research sites.
Participants in the study said they were accelerating their move to digital clinical systems with 45% of the participants indicating the adoption of digital technologies is a top priority for them in the coming year. The move is expected to make it easier for collaboration, thereby increasing trial efficiency, accelerating data delivery and improving the experience for sites.